Ubs Group Ag Cardiol Therapeutics Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 234,818 shares of CRDL stock, worth $255,951. This represents 0.0% of its overall portfolio holdings.

Number of Shares

234,818

Previous 2,650 8761.06%

Holding current value

$255,951

Previous $5,000 5940.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.25 - $2.07 $290,210 - $480,587	232,168 Added 8761.06%	234,818 $302,000
Q3 2024 Nov 14, 2024	BUY	$1.83 - $2.48 $274 - $372	150 Added 6.0%	2,650 $5,000
Q2 2024 Aug 13, 2024	SELL	$1.67 - $2.97 $469 - $834	-281 Reduced 10.1%	2,500 $5,000
Q1 2024 May 13, 2024	SELL	$0.88 - $2.06 $2,578 - $6,035	-2,930 Reduced 51.3%	2,781 $5,000
Q4 2023 Feb 09, 2024	BUY	$0.67 - $1.0 $2,111 - $3,151	3,151 Added 123.09%	5,711 $4,000
Q3 2023 Nov 09, 2023	BUY	$0.76 - $1.19 $45 - $71	60 Added 2.4%	2,560 $2,000
Q2 2023 Aug 11, 2023	SELL	$0.45 - $0.97 $8,120 - $17,504	-18,046 Reduced 87.83%	2,500 $2,000
Q1 2023 May 12, 2023	BUY	$0.47 - $0.81 $4,481 - $7,723	9,535 Added 86.6%	20,546 $10,000
Q4 2022 Feb 08, 2023	BUY	$0.48 - $1.0 $4,325 - $9,011	9,011 Added 450.55%	11,011 $5,000
Q3 2022 Nov 10, 2022	SELL	$1.02 - $1.41 $3,581 - $4,950	-3,511 Reduced 63.71%	2,000 $2,000
Q2 2022 Aug 10, 2022	SELL	$1.03 - $2.05 $3,393 - $6,754	-3,295 Reduced 37.42%	5,511 $7,000
Q1 2022 May 16, 2022	BUY	$1.25 - $2.31 $4,298 - $7,944	3,439 Added 64.08%	8,806 $13,000
Q4 2021 Feb 14, 2022	BUY	$1.83 - $4.86 $9,821 - $26,083	5,367 New	5,367 $10,000

Others Institutions Holding CRDL

# of Institutions

Shares Held

7.63M

Call Options Held

4.9K

Put Options Held

3.8K

View Full List

About Cardiol Therapeutics Inc.

Ticker CRDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 61,942,500
Market Cap $67.5M
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...

More about CRDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account